
    
      The study will be conducted in 2 parts: dose escalation and dose expansion. The study will
      evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of
      Talquetamab administered to adult participants with relapsed or refractory multiple myeloma.
      The overall safety of the study drug will be assessed by physical examinations, Eastern
      Cooperative Oncology Group performance status, laboratory tests, vital signs,
      electrocardiograms, adverse event monitoring, and concomitant medication usage. Disease
      evaluations will include peripheral blood and bone marrow assessments at screening (performed
      within 28 days) and to confirm stringent complete response (sCR), complete response (CR), or
      relapse from CR. The end of study (study completion) is defined as the last study assessment
      for the last participant in the study. Study record NCT04634552 is Phase 2 part of this study
      and study record NCT03399799 is Phase 1 part of this study.
    
  